Your unrestricted view into eyecare conferences across the spectrum. Gain exclusive access to Ophthalmology Times® expert-led conference coverage from major meetings throughout the year featuring articles, videos, and insights shared by prominent experts of the ophthalmic community.
Topical treatment improves corneal healing in pediatric patients with neurotrophic keratitis
April 23rd 2022In an e-poster presented at the American Society of Cataract and Refractive Surgery’s 2022 annual meeting in Washington, D.C., Abdelrahman M. Elhusseiny, MD, MSc, noted a research team found that cenegermin was effective for improving the corneal healing in these pediatric patients.
Unity provides Phase 1 study data for UBX1325
February 14th 2022During a presentation at the Bascom Palmer Eye Institute Angiogenesis, Exudation, and Degeneration 2022 conference, Robert Bhisitkul, MD, PhD, provided 24-week clinical data from the Phase 1 study, demonstrating that patients with DME and wAMD showed improved visual acuity through 24 weeks following a single dose of UBX1325.
Glaucoma 360: Exploring remote monitoring of glaucoma
February 12th 2022Oluwatosin U. Smith, MD, associate professor in the Department of Ophthalmology, University of Texas Southwestern, Dallas, speaks with Ophthalmology Times'® Sheryl Stevenson on the highlights of her presentation exploring remote monitoring of glaucoma and the future of virtual care on the whole.
Glaucoma 360: Rising from the pandemic: Glaucoma drug delivery
February 12th 2022During the Glaucoma 360 New Horizons Forum, the spotlight was cast upon sustained release injectables, including innovations that have been flourishing over the past year despite, or perhaps because of, a continuing worldwide pandemic.
DAVIO trial finds positive safety results for EYP-1901 for wet AMD
February 12th 2022Jay S. Duker, MD, who presented data at the Bascom Palmer Eye Institute’s 19th annual Angiogenesis, Exudation, and Degeneration 2022 Virtual Edition, noted that previously treated patients showed a significantly reduced treatment
Novel devices, drugs driving expansion in glaucoma market
February 11th 2022The introduction of new devices is possibly the single most influential factor currently driving the glaucoma market, said Kristen Harmon Ingenito, MBA, in her presentation during the New Horizons Forum at the 2022 Glaucoma 360.
Glaucoma 360: Science fiction or science fact in eye care
February 11th 2022Ranya Habash, MD, medical director of Technology Innovation, assistant professor of Clinical Ophthalmology at Bascom Palmer Eye Institute, University of Miami in Miami, Florida, offers a preview of her New Horizons keynote speech on "The future of eye care: science fiction to science fact."
Post hoc analysis of patients in avacincaptad pegol clinical trial shows growth of GA lesions slowed
February 11th 2022In a presentation at the Bascom Palmer Eye Institute’s 19th annual Angiogenesis, Exudation, and Degeneration 2022 Virtual Edition, Glenn J. Jaffe, MD, noted that the analysis showed, for the first time, a decreased growth rate in the central foveal area by a therapeutic intervention when compared with sham treatment.